Evidence map›Paper›PMID 40649382›Full record

ReviewMolecules (Basel, Switzerland)2025

Strategies Used for the Discovery of New Microbial Metabolites with Antibiotic Activity.

Pablo Dasí-Delgado, Cecilia Andreu, Marcel Lí Del Olmo

Abstract readReview
In one paragraph

Review in Molecules (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Biosynthesized Silver Nanoparticles FromInternational journal of microbiology · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Pablo Dasí-DelgadoDepartament de Bioquímica i Biologia Molecular, Universitat de València (UVEG), Dr. Moliner 50, E-46100 Burjassot, València, Spain.
Cecilia AndreuDepartament de Química Orgànica, Universitat de València (UVEG), Vicent Andrés Estellés s.n., E-46100 Burjassot, València, Spain.ORCID 0000-0003-2324-9944
Marcel Lí Del OlmoDepartament de Bioquímica i Biologia Molecular, Universitat de València (UVEG), Dr. Moliner 50, E-46100 Burjassot, València, Spain.ORCID 0000-0002-8682-6369

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The discovery of new microbial metabolites is essential to combat the alarming rise in antimicrobial resistance and to meet emerging medical needs. This work critically reviews current strategies for identifying antimicrobial compounds, emphasizing the potential of microorganisms as a rich source of bioactive secondary metabolites. This review explores innovative methods, such as investigating extreme environments where adverse conditions favor the emergence of unique metabolites; developing techniques, like the iChip, to cultivate previously uncultivable bacteria; using metagenomics to analyze complex samples that are difficult to isolate; and integrates artificial intelligence to accelerate genomic mining, structural prediction, and drug discovery optimization processes. The importance of overcoming current challenges, such as replicating findings, low research investment, and the lack of adapted collection technologies, is also emphasized. Additionally, this work analyzes the crucial role of bacterial resistance and the necessity of a holistic approach involving new technologies, sustained investment, and interdisciplinary collaboration. This work emphasizes not only the current state of metabolite discovery but also the challenges that must be addressed to ensure a continuous flow of new therapeutic molecules in the coming decades.

Indexed as

Anti-Bacterial AgentsBacteriaDrug DiscoveryDrug Resistance, BacterialHumansMetagenomicsAnti-Bacterial Agentsantibioticantimicrobial resistanceartificial intelligencedrug discoveryextremophilesisolation Chipmetagenomicsmicroorganismsnatural productssecondary metabolites

Identifiers

PMID40649382
PMCPMC12251386

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.